Introduction: Fusion anomalies of the testis and epididymis are associated with cryptorchidism. We present an analysis of the fusion anomalies of the epididymis in cryptorchid boys. Patients and Methods: We performed a retrospective review of patients presenting with undescended testes between 1986 and 1993. Patients were stratified among four groups based on the degree of testis-epididymis nonfusion. Results: A total of 880 testes were eligible for review, of which 93% (815/880) had normal fusion, 3.6% (32/880) had epididymal head nonfusion, 2% (19/880) had epididymal tail nonfusion, and 1.6% (14/880) had complete nonfusion. Increasing degree of nonfusion was associated with higher perioperative testes position. Head and tail nonfusion were observed together with a contralateral descended testis, but less frequently than in bilateral undescended testes (p = 3.89×E–10). Complete nonfusion was not observed in the contralateral descended testes in unilateral cryptorchid boys. Conclusions: Different degrees of fusion anomalies of the epididymis are associated with unilateral and bilateral undescended testis, indicating that nonfusion anomalies interact with epididymal-testicular descent because of impaired epididymal function.

Keywords:
Cryptorchidism, Epididymis, Undescended testis, Epididymal fusion anomalies, Contralateral descended testis
1.
Michelson L: Congenital anomalies of the ductus deferens and epididymis. J Urol 1949;61:384–390.
2.
Scorer CG, Farrington GH: Congenital Deformities of the Testis and Epididymis. New York, Appleton-Century-Crofts, 1971, pp 136–146.
3.
Marshal FF, Shermeta DW: Epididymal abnormalities associated with undescended testis. J Urol 1979;121:341–343.
4.
Gutierrez A, Campos A, Canizares FJ, Crespo PV, Sanchez C: Anatomical and clinical correlation with histological and histometric patterns in cryptorchidism. Br J Urol 1993;72:506–509.
5.
Merksz M, Toth J: Testicular-epididymal fusion abnormality in undescended testis. Int Urol Nephrol 1987;19:179–187.
6.
Gill B, Kogan S, Starr S, Reda E, Levitt S: Significance of epididymal and ductal anomalies associated with testicular maldescent. J Urol 1989;142:556–558.
7.
Koff WJ, Scaletscky R: Malformations of the epididymis in undescended testis. J Urol 1990;143:340–343.
8.
Mollaeian M, Mehrabi V, Elahi B: Significance of epididymal and ductal anomalies associated with undescended testis: study in 652 cases. Urology 1994;43:857–860.
9.
Kraft K, Mucksavage P, Canning D, Snyder H, Kolon T: Histological findings in patients with cryptorchidism and testis-epididymis nonfusion. J Urol 2011;186:2045–2049.
10.
Hadziselimovic F, Adham I: Insulin 3-like hormone and its role in epididymo-testicular descent. Int Braz J Urol 2007;33:407–411.
11.
Pearls AH, Scott EA, Cox JE: Monorchidism in the horse. Equine Vet J 1989;21:215–217.
12.
Hadziselimovic F: Funktionelle Morphologie und Pathologie der Nebenhoden und ihr Einfluss auf den Descensus Testiculorum. Morphol Med 1981;1:31–42.
13.
Hadziselimovic F: Mechanism of testicular descent. Urol Res 1984;12:155–157.
14.
Ikadai H, Ajisawa C, Tsujimura S, Watanabe G, Taya K Imamichi T: A new male pseudohermaphrodite rat mutant with androgen deficiency. J Reprod Fertil 1988;84:303–312.
15.
Hadziselimovic F: Pathogenesis of cryptorchidism; in Kogan SJ, Hafez ESE (eds): Pediatric Andrology. The Hague, Martinus Nijhoff, 1981, pp 147–162.
16.
Bica DTG, Hadziselimovic F: Buserelin treatment of cryptorchidism: a randomized, double-blind, placebo controlled study. J Urol 1992;148:617–621.
17.
Bica DTG, Hadziselimovic F: The behavior of epididymis, processus vaginalis, and testicular descent in cryptorchid boys treated with buserelin. Eur J Pediatr 1993;52(suppl 2):S38–S42.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.